Apellis Pharmaceuticals (APLS) Revenue & Revenue Breakdown
Apellis Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$366.28M
Latest Revenue (Q)
$176.57M
Main Segment (Y)
Product
Apellis Pharmaceuticals Revenue by Period
Apellis Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $366.28M | 385.64% |
2022-12-31 | $75.42M | 13.31% |
2021-12-31 | $66.56M | -73.44% |
2020-12-31 | $250.65M | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | - |
Apellis Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $176.57M | -11.58% |
2024-06-30 | $199.69M | 15.88% |
2024-03-31 | $172.32M | 17.73% |
2023-12-31 | $146.38M | 47.58% |
2023-09-30 | $99.18M | 4.44% |
2023-06-30 | $94.97M | 111.77% |
2023-03-31 | $44.85M | 97.88% |
2022-12-31 | $22.66M | 2.75% |
2022-09-30 | $22.06M | 35.13% |
2022-06-30 | $16.32M | 13.50% |
2022-03-31 | $14.38M | -76.15% |
2021-12-31 | $60.29M | 967.08% |
2021-09-30 | $5.65M | 806.90% |
2021-06-30 | $623.00K | 100.00% |
2021-03-31 | - | -100.00% |
2020-12-31 | $250.00M | 38599.69% |
2020-09-30 | $646.00K | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | -100.00% |
2019-12-31 | $-142.15K | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | -100.00% |
2018-12-31 | $11.54K | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | -100.00% |
2017-12-31 | $11.54K | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | - |
Apellis Pharmaceuticals Revenue Breakdown
Apellis Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
---|---|---|---|---|
Product | $366.28M | $65.09M | $15.15M | - |
Licensing And Other Revenue | $30.31M | $10.33M | $51.42M | - |
Collaboration | - | - | - | $152.00K |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product | $176.57M | $179.14M | $163.07M | $138.65M | $99.18M | $89.64M | $38.80M | $19.65M | $17.68M | $15.65M | $12.11M | $9.21M | $5.31M |
Licensing And Other Revenue | $20.26M | $20.55M | $9.25M | $7.72M | $11.22M | $5.32M | $6.05M | $3.01M | $4.38M | $668.00K | $2.27M | $51.08M | $336.00K |
Latest
Apellis Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
MREO | Mereo BioPharma Group | $10.00M | - |
XFOR | X4 Pharmaceuticals | - | $560.00K |
IMVT | Immunovant | - | - |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
TERN | Terns Pharmaceuticals | - | - |
AKRO | Akero Therapeutics | - | - |